EGFR Exon 19 Deletion
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy (NCT05338970) | Daiichi Sankyo | 2022-07-08 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
Track EGFR Exon 19 Deletion automatically
Every clearance here is in the API, with alerts when new ones post.